Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>=18 years, either sex, any race.~* Eastern Cooperative Oncology Group performance status of 0, 1, or 2.~* There must be no known standard therapy, or disease must be refractory to standard therapy~* Adequate hematologic, renal, and hepatic organ function and laboratory parameters~* For advanced solid tumors, non-Hodgkin's lymphoma, or multiple myeloma:~  * Participants must have histologically proven solid tumors, non-Hodgkin's lymphoma, or multiple myeloma.~ * Evaluable malignancy must be present by computed tomography or magnetic resonance imaging, obtained within 4 weeks prior to the start of treatment with SCH 727965.~* Subjects with multiple myeloma must have measurable disease defined as:~  * Serum monoclonal protein greater than 0.5 g/dL or urine light chain excretion of greater than 0.2 g/24-hour obtained within 4 weeks prior to the start of treatment.~ * Participants with lower M protein values or nonsecretory myeloma are eligible if measurable disease can be established within 4 weeks prior to start of treatment, such as:~    * serum free light chain ratio greater than 5 times the normal ratio limit; and/or~   * measurable soft tissue plasmacytoma greater than 2 cm, by either physical examination and/or applicable radiographs; and/or~   * bone marrow involvement greater than 30%.~* For B-cell chronic lymphocytic leukemia (B-CLL):~  * Diagnosis of B-CLL according to the National Cancer Institute Working Group (NCI-WG) criteria or a histological diagnosis of small lymphocytic lymphoma.~ * Disease must be evaluable according to NCI-WG response criteria.~Exclusion Criteria:~* Symptomatic brain metastases or primary central nervous system malignancy.~* Previous radiation therapy to \>25% of the total bone marrow.~* Previous treatment with SCH 727965.~* Known HIV infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Advanced solid tumors (Type: EXPERIMENTAL): Participants with advanced solid tumors treated with SCH 727965 in dose-escalation cohorts
- Non-Hodgkin's lymphoma and multiple myeloma (Type: EXPERIMENTAL): Participants with non-Hodgkin's lymphoma or multiple myeloma treated with SCH 727965
- B cell chronic lymphocytic leukemia (Type: EXPERIMENTAL): Participants with B-cell chronic lymphocytic leukemia treated with SCH 727965 in dose-escalation cohorts

Based on this trial design, predict the completion outcome and termination type (if applicable).